Nivolumab in advanced melanoma treament
Tapia-López E, Ciapponi A, Gonzalez L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L
Record ID 32016001132
Spanish
Authors' recommendations:
Moderate quality evidence showed that the use of nivolumab, when compared with dacarbazine in patients with advanced melanoma (metastatic or inoperable) would increase survival rate at one year and progression-free survival as first line. Although its use as single-agent or in combination with ipilimumab showed an increased progression-free survival, the lack of information on its impact on overall survival or comparative studies against other current first line treatment options (pembrolizumab or BRAF inhibitors) limit its recommendation as treatment alternative.
Clinical practice guidelines recommend its use as an additional alternative for first and/or second line treatment. The health technology assessments identified differ regarding use recommendations of this drug.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Nivolumab
- Melanoma
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.